Literature DB >> 17495417

Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine.

Yusuke Hara1, Miki Nakajima, Ken-ichi Miyamoto, Tsuyoshi Yokoi.   

Abstract

Morphine is an analgesic drug used for the treatment of acute and chronic pain syndromes for cancer patients. Glucuronidation is a major pathway of the elimination of morphine in humans. Morphine is metabolized to 3-glucuronide (no analgesic effect) and 6-glucuronide (more potently analgesic than morphine) mainly by UGT2B7. In the present study, we investigated the inhibitory effects of a variety of drugs on the morphine glucuronosyltransferase activities in human liver microsomes. Twenty-one drugs including anticancer drugs, immunosuppressants, analgesics, anticonvulsants, antidepressants, antipsychotic drugs were selected in this study, because they are frequently co-administered with morphine. We found that 10 out of 21 drugs, tamoxifen, tacrolimus, diclofenac, carbamazepine, imipramine, clomipramine, amitriptyline, diazepam, lorazepam and oxazepam extensively inhibited the morphine 3- and 6-glucuronosyltransferase activities. Although some of the drugs are not substrates of UGT2B7, they would be potent inhibitors of UGT2B7. If patients receive morphine and these drugs simultaneously, the drug-drug interaction may change the levels of morphine and these glucuronides, resulting in altered analgesic efficacy and the risk of side effects. The results presented here will assist clinicians in choosing the proper drugs and/or dosages, and enable them to anticipate potential drug-drug interactions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17495417     DOI: 10.2133/dmpk.22.103

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  8 in total

1.  An in vitro approach to estimate putative inhibition of buprenorphine and norbuprenorphine glucuronidation.

Authors:  Stephanie Oechsler; Gisela Skopp
Journal:  Int J Legal Med       Date:  2010-01-29       Impact factor: 2.686

2.  Data Mining FAERS to Analyze Molecular Targets of Drugs Highly Associated with Stevens-Johnson Syndrome.

Authors:  Keith K Burkhart; Darrell Abernethy; David Jackson
Journal:  J Med Toxicol       Date:  2015-06

Review 3.  Opioid metabolism.

Authors:  Howard S Smith
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

4.  PharmGKB summary: carbamazepine pathway.

Authors:  Caroline F Thorn; Susan G Leckband; John Kelsoe; J Steven Leeder; Daniel J Müller; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-12       Impact factor: 2.089

5.  [Interaction of opioid analgesics at the level of biotransformation].

Authors:  H Petri; D Grandt
Journal:  Schmerz       Date:  2016-12       Impact factor: 1.107

6.  Pharmacokinetics of Morphine in Rats with Adjuvant-induced Arthritis.

Authors:  Yoshiaki Kimura; Mika Shibata; Mika Tamada; Noriyuki Ozaki; Kunizo Arai
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

7.  Editorial: Metabolism of anti-cancer drugs: Interplay involving pharmacology and pharmacokinetics.

Authors:  Tashinga E Bapiro; Rose Hayeshi; Collet Dandara
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

Review 8.  The Impact of Anti-Epileptic Drugs on Growth and Bone Metabolism.

Authors:  Hueng-Chuen Fan; Herng-Shen Lee; Kai-Ping Chang; Yi-Yen Lee; Hsin-Chuan Lai; Pi-Lien Hung; Hsiu-Fen Lee; Ching-Shiang Chi
Journal:  Int J Mol Sci       Date:  2016-08-01       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.